Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

@inproceedings{Davis2014DeregulationOT,
  title={Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention},
  author={Nicole M. Davis and Melissa L. Sokolosky and Kristin M. Stadelman and Stephen L. Abrams and Massimo Libra and Saverio Candido and Ferdinando Nicoletti and Jerry Polesel and Roberta Maestro and Antonino B. D’Assoro and Lyudmyla B. Drobot and Dariusz Rakus and Agnieszka Gizak and Piotr M. Laidler and Joanna Dulińska-Litewka and Joerg Basecke and Sanja Mijatovi{\'c} and Danijela Maksimovi{\'c}-Ivani{\'c} and Giuseppe Montalto and Melchiorre Cervello and Timothy L Fitzgerald and Zoya N. Demidenko and Alberto Maria Martelli and Lucio Cocco and Linda S. Steelman and James A McCubrey},
  booktitle={Oncotarget},
  year={2014}
}
The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a… CONTINUE READING
68 Citations
333 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 333 references

Similar Papers

Loading similar papers…